Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 16/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21631796 | 1.00 | EPHX2 (0.41) | EPHX2GPR119NAMPTEPHX1CYP2C9 | |
| SCHEMBL29455961 | 1.00 | EPHX2 (0.41) | EPHX2GPR119NAMPTEPHX1CYP2C9 | |
| SCHEMBL30531742 | 1.00 | EPHX2 (0.41) | EPHX2GPR119NAMPTEPHX1CYP2C9 | |
| SCHEMBL30158231 | 1.00 | EPHX2 (0.41) | EPHX2GPR119NAMPTEPHX1CYP2C9 | |
| SCHEMBL31184218 | 1.00 | EPHX2 (0.41) | EPHX2GPR119NAMPTEPHX1CYP2C9 | |
| SCHEMBL22084448 | 1.00 | EPHX2 (0.41) | EPHX2GPR119NAMPTEPHX1CYP2C9 | |
| SCHEMBL16925230 | 1.00 | EPHX2 (0.41) | EPHX2GPR119NAMPTEPHX1CYP2C9 | |
| SCHEMBL16925035 | 1.00 | EPHX2 (0.41) | EPHX2GPR119NAMPTEPHX1CYP2C9 | |
| SCHEMBL21631735 | 0.91 | EPHX2 (0.43) | EPHX2GPR119NAMPTEPHX1 | |
| SCHEMBL21064222 | 0.91 | EPHX2 (0.43) | EPHX2GPR119NAMPTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310771-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| EP-3310774-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-14 | — | — | US | disclosed |
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-09-06 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN3, PTPN1, PTPN2 | EPHX2 2323/4885GPR119 716/4885NAMPT 4370/4885 |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN2 | EPHX2 2716/4885GPR119 630/4885NAMPT 4208/4885 |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN3, PTPN1, PTPN2 | EPHX2 2323/4885GPR119 716/4885NAMPT 4370/4885 |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN2 | EPHX2 2682/4885GPR119 650/4885NAMPT 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.